The 10 Companies Booming in Healthcare Sector

More documents

Recommendations

Info

Interview with Insights Care Mr. Sy Ming Yiu CEO SANOMICS Improving Healthcare with Innovation and Compassion The healthcare industry is looking for better answers to diagnose and treat various life-threatening diseases we hear of today. One of these diseases that the industry is trying to combat since long is cancer. Although there have been various advancements related to cancer treatment, no specific solution is reached yet. By far, the best possible solution comes from gene therapy. Apart from cancer treatment, gene therapy has showed a lot of potential to improve the treatment of number of deadly diseases. Sanomics is a fast-growing company, which is contributing relentlessly to the future of healthcare with novel gene therapy solutions. It is remarkably revolutionizing cancer treatments for the patients with safe and efficient liquid-based and tissuebased genomic tests. To know more about the story of this ingenious company, we at Insightscare bring to you an exclusive interview with its CEO, Mr. Sy Ming Yiu, Stanley. 1. Tell us in brief about Sanomics Limited. Established in Hong Kong Science and Technology Parks Corporation in 2015, Sanomics Limited is a Hong Kong based biotechnology start-up that specializes in liquid biopsy and tissue-based genomic diagnostics for cancer patients, so as to help doctors decide personalized cancer solutions for patients. Since 2015, Sanomics’ service covers 20 countries and regions and it has completed more than 7,000 patient cases over the world. Sanomics (Thailand) Limited was founded in October 2018 in Bangkok, which is the first Hong Kong biotechnology start-up launched in Thailand. Focusing on lung and women cancer, Sanomics’ comprehensive cancer genomic screening services covers both somatic mutation and germline mutations, adopting Droplet Digital Polymerase Chain Reaction (ddPCR), Next Generation Sequencing (NGS) technology to complete Comprehensive Genomic Profiling (CGP), and Real-time Polymerase Chain Reaction (Real-time PCR). 16 | June 2019 |
2. What were the motivating factors that led towards the inception of the company? “Patient first” is absolutely the most motivating factor. An accurate genomic test result is critical for helping doctors to design a personalized treatment for cancer patients. We strive to provide the genomic tests which are of higher quality, cheaper price, and quicker turnaround time to help cancer patients to save time and medical expenses. 3. Which is your flagship product? Also, tell us how Sanomics stands tall and differentiates itself from others in this competitive world. ® Requiring only 20ml of blood and 2 working days of turnaround time, p-EGFR liquid biopsy test detects the EGFR gene mutation which causes lung cancer. Comparing with traditional tissue biopsy which is an invasive operation, costly, and ® ® time consuming, p-EGFR is non-invasive, affordable, and quick. Since the launch of p-EGFR in August 2015 in Hong Kong, it has become the market leader in Hong Kong within just 8 months. What makes Sanomics stand out is our dedication to execution. We always emphasis the innovation of Sanomics is in execution. Ranging from test request, specimen collection to release report, we try our best to keep the process as simple as possible, so that physicians’ precious time can be spent on treating patients instead of dealing with clumsy procedures. For example, we simplify the process of requesting Sanomics’ tests to 3 steps only and keep our form and test report in 1 page to save time of physicians. Also, we launched Sanomics Portal mobile app for doctors to keep posted. 4. What are all the products and services that Sanomics Limited provides? ® The pEGFR test screens for the presence of Exon 19 deletions, Exon 21 L858R, Exon 20 T790M, C797S mutations in blood specimens using droplet digital PCR technology. This test is useful for assessing and monitoring whether TKI therapies would be effective mostly for lung cancer patients. The pBRAF V600ETM test screens for the presence of BRAF V600E mutation in blood specimens using droplet digital PCR technology. The test targets lung, thyroid, colorectal, and melanoma and it is useful for assessing whether the indicated therapies would be useful. It is suggested that if the test results are positive, dabrafenib, and trametinib can be used as targeted therapy. Guardant360® identifies somatic mutations of 73 genes, proven to be clinically relevant, and reports on microsatellite instability (MSI) status through the detection of circulating tumor DNA (ctDNA) in blood specimens using NGS technologies. The test is suitable for patients with advanced solid tumors. The report would present targeted treatment options including approved therapies and therapies undergoing late-stage clinical trials, as well as immunotherapy options. The test would be performed in the US. BRCA Zoom® identifies germline mutation of BRCA1 and BRCA2. The test is suitable for patients who have been diagnosed with breast, ovarian, prostate, and pancreatic cancer; people with family history of the above mentioned cancer and other cancer high-risk groups. Each person carries BRCA1 and BRCA2 genes. These two genes are mainly responsible for repairing damaged DNA and maintaining stable cell growth. If a person carries a mutation of the BRCA gene, the risks of developing breast, ovarian, prostate cancer or pancreatic cancer in a lifetime also increases. Also, the family members of that person would also have a possibility of carrying the mutated BRCA genes. | June 2019 | 17
Page 1: 2019 Vol.6/ Issue-2 www.insightscar
Page 5 and 6: Editor’s Column
Page 7 and 8: CONTENTS 24 32 34 David Health Solu
Page 9: Editor-in-Chief Pooja M. Bansal Sen
Page 13 and 14: Cover Story NOVOTECH A Catalyst for
Page 15 and 16: ” We maintain and monitor the qua
Page 20 and 21: OncoSnap® is a pioneering tumor ti
Page 24 and 25: Tania Martin-Mercado Chief Technolo
Page 26 and 27: ‘‘ ‘‘ eadquarter in Helsink
Page 28 and 29: patients care for a variety of musc
Page 30 and 31: In-house Opinion Social Media Marke
Page 32: Healthcare industry is also affecte
Page 35 and 36: Eclectic Services Accutest provides
Page 37 and 38: across the US and outside the US, i
Page 39 and 40: Novel Discoveries Top Health Tech I
Page 41: ROBOTIC SURGERY Robotics has been a

The 10 Companies Booming in Healthcare Sector

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?